3,618 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG bought a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,618 shares of the medical research company's stock, valued at approximately $546,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in shares of Quest Diagnostics by 1.6% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 3,843 shares of the medical research company's stock worth $580,000 after acquiring an additional 60 shares during the last quarter. Net Worth Advisory Group lifted its stake in Quest Diagnostics by 1.0% in the 4th quarter. Net Worth Advisory Group now owns 6,495 shares of the medical research company's stock valued at $980,000 after purchasing an additional 62 shares during the last quarter. Bessemer Group Inc. lifted its stake in Quest Diagnostics by 0.3% in the 4th quarter. Bessemer Group Inc. now owns 20,811 shares of the medical research company's stock valued at $3,140,000 after purchasing an additional 65 shares during the last quarter. Brooklyn Investment Group boosted its position in Quest Diagnostics by 5.5% in the fourth quarter. Brooklyn Investment Group now owns 1,315 shares of the medical research company's stock valued at $198,000 after buying an additional 68 shares in the last quarter. Finally, Mather Group LLC. grew its stake in shares of Quest Diagnostics by 10.4% during the fourth quarter. Mather Group LLC. now owns 764 shares of the medical research company's stock worth $115,000 after buying an additional 72 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DGX shares. Redburn Atlantic started coverage on Quest Diagnostics in a report on Wednesday, April 2nd. They set a "buy" rating and a $195.00 price target on the stock. Redburn Partners set a $195.00 target price on shares of Quest Diagnostics in a report on Wednesday, April 2nd. StockNews.com downgraded shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Thursday, February 6th. UBS Group lifted their price target on shares of Quest Diagnostics from $166.00 to $170.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Finally, Piper Sandler increased their price objective on Quest Diagnostics from $180.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, April 28th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $185.73.

Quest Diagnostics Trading Up 0.0%

NYSE:DGX traded up $0.06 during trading hours on Tuesday, hitting $178.18. The company had a trading volume of 994,516 shares, compared to its average volume of 984,021. The stock has a 50-day moving average price of $170.27 and a 200 day moving average price of $163.82. Quest Diagnostics Incorporated has a 52 week low of $135.47 and a 52 week high of $182.20. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.10 and a quick ratio of 1.02. The company has a market capitalization of $19.89 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 2.16 and a beta of 0.52.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.63 billion. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 21st. Shareholders of record on Monday, July 7th will be paid a dividend of $0.80 per share. The ex-dividend date is Monday, July 7th. This represents a $3.20 dividend on an annualized basis and a yield of 1.80%. Quest Diagnostics's dividend payout ratio is presently 40.46%.

Insider Activity

In related news, SVP Michael E. Prevoznik sold 528 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $172.61, for a total value of $91,138.08. Following the completion of the transaction, the senior vice president now directly owns 39,031 shares of the company's stock, valued at approximately $6,737,140.91. This trade represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mark E. Delaney sold 874 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the transaction, the senior vice president now owns 8,372 shares of the company's stock, valued at $1,471,127.84. This trade represents a 9.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,124 shares of company stock valued at $9,341,875 in the last ninety days. 8.16% of the stock is currently owned by company insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.